Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO December 2019
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: Cantargia at a glance
Cantargia at a glance Unique immunotherapy antibody CAN04 in phase IIa clinical development ▪ Positive interim data set with response rates higher than historic data Current owners (30 Sep 2019) ▪ Further phase II milestones during 2020 Platform with many potential therapeutic areas Sunstone 7.5% ▪
Slide 4: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value → Potentially more effective treatment against novel target in clinically validated pathway → Right team and clear plan to position our projects and maximize value → First in class platform technology against novel target 4
Slide 5: Cantargia addresses a huge market
Cantargia addresses a huge market Incidence, Globally 2018 Mortality, Globally 2018 Type of cancer: Type of cancer: Lung: 22,6% Lung: 18,4% Lung cancer Pancreatic cancer Other: Other: 42,9% 35,8% Breast: Breast: 6,6% Incidence 2018 11,6% 2,093,876 458,918 Bowel: (globally) 9,2% Bowel: 10,2% Fraction
Slide 6: Lead antibody CAN04
=a (=) 2 <x (Ss) > mo} ° 2 r=) c © mo} is) ov 4
Slide 7: CAN04 – Mechanism of action
CAN04 – Mechanism of action 7 Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated Fibroblast. NK = Natural Killer. MCP = Monocyte Chemoattractant Protein. MMP = Matrix Metallopeptidase. IL = Interleukin. VEGF = Vascular Endothelial Growth Factor
Slide 8: Validating study – Counteracting tumor inflammation
Validating study – Counteracting tumor inflammation CANTOS trial (n=10,061) Canakinumab phase III trials ▪ Canakinumab (Novartis) ▪ Reduced lung cancer incidence by 67% and death by 77% Adjuvant NSCLC ▪ 1,500 patients ▪ Reduced non-lung cancer death by 37% 3 (CANOPY-A) ▪ After surgery, no mets, plac
Slide 9: CAN04 – Superior MoA against other IL-1 blocking approaches
CAN04 – Superior MoA against other IL-1 blocking approaches Company Compound IL-1α IL-1β ADCC Indication/dev phase • Pancreatic cancer, NSCLC Cantargia CAN04 ++ ++ ++ phase IIa • Autoimmunity Xbiotech Xilonix ++ – + • Pancreatic cancer, phase I • Autoimmunity, registered Canakinumab Novartis Gevokiz
Slide 10: Positive phase IIa interim combination data
Positive phase IIa interim combination data On Initiated Evaluable CR/PR SD PD therapy → By adding CAN04 response rates are higher than historical data using these standard first line chemo- PDAC 10 7 7 41) 32) therapies alone Historical 23% 27% 20% → 4 of 7 evaluable patients with metastatic pancre
Slide 11: Combination therapy – Response assessments
Combination therapy – Response assessments Cohort 1 (5 mg/kg) N1 2 4 6 ARM C (NSCLC) N2 2 4 N3 2 4 Months N4 Discontinued after V1 (IRR) Unconfirmed Confirmed Cohort 1 (5 mg/kg) CA19-9 >90% red Progressive disease 2 2 P1 Discountinued after V1 (IRR) P2 2 4 6 8 √ Pseudoprogression 2 2 P3 2 4 6 8 √ P4
Slide 12: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Dec PDAC NSCLC 2018 CANFOUR Q2 Q3 2020 2020 Phase I – Dose escalation Phase IIa – Dosage with assessment with safety assessment of therapeutic effect Monotherapy Combination therapy, NSCLC (Dose group X) Recommended phase II dose Combination therapy, PDAC Dose group 3
Slide 13: Pancreatic cancer strategy
Pancreatic cancer strategy Subgroup Share (USA) Treatment Target Resectable 10% Surgery Cure Locally advanced 29% Chemotherapy Response, surgery Metastatic 52% Chemotherapy Response → USA: Estimate 57,000 cases 2019, 5 year survival rate Resectable 34%, Locally advanced 12%, Metastatic 3% → Preparat
Slide 14: Chemotherapy resistance
Chemotherapy resistance → Most chemotherapies induce chemoresistance already after a few months of therapy → Several recent studies show chemotherapy induction of IL-1 leading to resistance → Blocking IL-1 signalling counteracts chemoresistance in preclinical models → High blood levels of inflammato
Slide 15: Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine
Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine Tumor growth Ctrl CIS GEM CIS/GEM CIS/GEM + CAN04 2 000 → CAN04 increases antitumor effects of platinum 1 500 compounds (cisplatin, carboplatin, oxaliplatin) Tumor volume (mm3) 1 000 500 0 → CAN04 counteracts toxicity from platin
Slide 16: CMC – Summary of transfer to Patheon
CMC – Summary of transfer to Patheon ▪ Processing method Technology transfer ▪ Equipment ▪ Analytical methods ▪ Assure GMP compliance Scale-up and first batch ▪ Product testing to confirm equivalence with at new production scale previous produced product ▪ 2,000 liter scale Phase III readiness and ▪
Slide 17: CAN04 oncology expansion
c 2 7) c is) a x< oO > Loe) 2 ° ° c ° =a (=) 2 <x (Ss)
Slide 18: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need IL1RAP Cantargia ▪ Discovery of IL1RAP on cancer cells founded ▪ Antibodies against IL1RAP – antitumor effects 120 based on ▪ IP on antibody therapy against IL1RAP 100 Primary ▪ Non-small cell lung cancer – NSCLC 80 indications ▪ Pancreatic cancer – PD
Slide 19: IL1RAP and PD-1 blockade – Rationale for combination study
IL1RAP and PD-1 blockade – Rationale for combination study ▪ Myeloid suppressive cells, such as tumor-associated macrophages (TAMs) or myeloid-derived suppressor cells (MDSCs) are key cells in PD-1 resistance and express IL1RAP and are stimulated by IL-1, these cells counteracts PD-1 blockade Chroni
Slide 20: US phase I clinical trial
US phase I clinical trial → PreIND meeting held, IND submission Jan 2020 → Combination with checkpoint inhibitor in patients that have relapsed PD1/PDL-1 therapy → Primary endpoint safety, secondary endpoints include biomarkers and efficacy → Indications include NSCLC, HNSCC and bladder cancer (18 p
Slide 21: Untapped possibilities in autoimmune diseases
Untapped possibilities in autoimmune diseases
Slide 22: IL1RAP platform to treat serious diseases
IL1RAP platform to treat serious diseases → Three different systems signal through IL1RAP → These systems contribute to various inflammatory diseases → Can be blocked by Cantargia’s antibodies against IL1RAP Unique opportunity by blocking several disease inducing cytokine 22
Slide 23: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in mouse model → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on s
Slide 24: CAN10 – Systemic sclerosis and myocarditis
CAN10 – Systemic sclerosis and myocarditis → Development process of CAN10 has included independent analysis of potential to treat c. 150 autoimmune and inflammatory diseases CAN10 → Analysis included statements from key opinion leaders regarding e.g. scientific rationale of the method blockade of th
Slide 25: CAN10 counteract inflammation in disease model
CAN10 counteract inflammation in disease model Total back score Isotype anti-IL-1β mCAN10 Dexamethasone 5 4 → Mechanistic proof of concept for IL1RAP blockade in Score (0-8) 3 inflammatory driven psoriasis model 2 → Effect not dependent on IL-1β blockade 1 0 0 1 2 3 4 5 6 7 Days CAN10 has unique ant
Slide 26: Milestones and summary
> re o E E S yn me} ¢c © i) oO ¢c ie} _~ n a =
Slide 27: Significant value inflection points
Significant value inflection points Newsflow in 2020 CAN04 → Checkpoint combination clinical trial, IND submission and start → Phase IIa combination results in PDAC and NSCLC → Phase IIa monotherapy biomarker/biopsy results → Phase IIa expansion of combination therapy CAN10 → Preclin in progress → T
Slide 28: Cantargia at a glance
Cantargia at a glance Unique immunotherapy antibody CAN04 in phase IIa clinical development ▪ Positive interim data set with response rates higher than historic data ▪ Further phase II milestones during 2020 Platform with many potential therapeutic areas ▪ IL1RAP found on most solid tumor forms and